Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, Passannanti P, Pontillo-Contillo B, Battaglia V, Mazzeo S, Molinaro E, Elisei R. Lorusso L, et al. Among authors: sabini e. Onco Targets Ther. 2016 Oct 20;9:6467-6477. doi: 10.2147/OTT.S84625. eCollection 2016. Onco Targets Ther. 2016. PMID: 27799794 Free PMC article. Review.
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati P, Puleo L, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo S, Vitti P, Elisei R. Viola D, et al. Among authors: sabini e. Endocr Relat Cancer. 2016 Apr;23(4):R185-205. doi: 10.1530/ERC-15-0555. Endocr Relat Cancer. 2016. PMID: 27207700 Review.
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R. Molinaro E, et al. Among authors: sabini e. Nat Rev Endocrinol. 2017 Nov;13(11):644-660. doi: 10.1038/nrendo.2017.76. Epub 2017 Jul 14. Nat Rev Endocrinol. 2017. PMID: 28707679 Review.
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.
Leo M, Sabini E, Ionni I, Sframeli A, Mazzi B, Menconi F, Molinaro E, Bianchi F, Brozzi F, Santini P, Elisei R, Nardi M, Vitti P, Marcocci C, Marinò M. Leo M, et al. Among authors: sabini e. J Endocrinol Invest. 2018 Mar;41(3):357-361. doi: 10.1007/s40618-017-0754-3. Epub 2017 Aug 30. J Endocrinol Invest. 2018. PMID: 28856610
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G, Ricci D, Nicolì F, Sabini E, Sframeli A, Brancatella A, Mantuano M, Dottore GR, Bucci I, Figus M, Nardi M, Latrofa F, Marcocci C, Marinò M. Lanzolla G, et al. Among authors: sabini e. J Endocrinol Invest. 2020 Dec;43(12):1759-1768. doi: 10.1007/s40618-020-01341-2. Epub 2020 Jun 25. J Endocrinol Invest. 2020. PMID: 32583374
Natural history of graves' orbitopathy after treatment.
Menconi F, Leo M, Sabini E, Mautone T, Nardi M, Sainato A, Sellari-Franceschini S, Vitti P, Marcocci C, Marinò M. Menconi F, et al. Among authors: sabini e. Endocrine. 2017 Aug;57(2):226-233. doi: 10.1007/s12020-016-1136-x. Epub 2016 Oct 5. Endocrine. 2017. PMID: 27709471
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.
Sabini E, Leo M, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M. Sabini E, et al. Eur Thyroid J. 2017 Sep;6(5):263-270. doi: 10.1159/000477803. Epub 2017 Jun 26. Eur Thyroid J. 2017. PMID: 29071239 Free PMC article.
43 results